RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAccording to pharma industry analysts, there is record-breaking undeployed dry powder available in private equity (PE) owned pharma assets requiring monetisation. Intensified PE investment in the pharma sector is poised to fuel accelerated M&A activity. All these trends consequently boost investor and consumer confidence,which is predicted to spur M&A activity in the pharma industry.
Dry powder—or uncommitted capital in the PE space—remains at a record high of nearly $4 trillion.
Arda Ural of Ernst and Young was quoted as estimating that pharma has $1.2 trillion in capital available for consideration of acquisitions.